m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02261)
Name
ELLAGIC ACID
Synonyms
ellagic acid; 476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728
    Click to Show/Hide
Status
Investigative
Structure
Formula
C14H6O8
InChI
1S/C14H6O8/c15-5-1-3-7-8-4(14(20)22-11(7)9(5)17)2-6(16)10(18)12(8)21-13(3)19/h1-2,15-18H
InChIKey
AFSDNFLWKVMVRB-UHFFFAOYSA-N
PubChem CID
5281855
TTD Drug ID
D0A1CM
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Glycogen synthase kinase-3 beta (GSK-3B)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for ELLAGIC ACID. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for ELLAGIC ACID. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). [2], [3]
Mothers against decapentaplegic homolog 3 (SMAD3)
ETS-related transcription factor Elf-3 (ELF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for ELLAGIC ACID. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [4], [5]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for ELLAGIC ACID. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [5], [6]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for ELLAGIC ACID. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [5], [7]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for ELLAGIC ACID. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [5], [8]
References
Ref 1 Vascular Smooth Muscle FTO Promotes Aortic Dissecting Aneurysms via m6A Modification of Klf5. Front Cardiovasc Med. 2020 Nov 20;7:592550. doi: 10.3389/fcvm.2020.592550. eCollection 2020.
Ref 2 Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93. doi: 10.1016/j.ejmech.2010.04.026. Epub 2010 Apr 28.
Ref 3 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 4 Involvement of Elf3 on Smad3 activation-dependent injuries in podocytes and excretion of urinary exosome in diabetic nephropathy. PLoS One. 2019 May 31;14(5):e0216788. doi: 10.1371/journal.pone.0216788. eCollection 2019.
Ref 5 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
Ref 6 N6-methyladenosine-induced circ1662 promotes metastasis of colorectal cancer by accelerating YAP1 nuclear localization. Theranostics. 2021 Feb 25;11(9):4298-4315. doi: 10.7150/thno.51342. eCollection 2021.
Ref 7 RNA demethylase ALKBH5 inhibits TGF-Beta-induced EMT by regulating TGF-Beta/SMAD signaling in non-small cell lung?cancer. FASEB J. 2022 May;36(5):e22283. doi: 10.1096/fj.202200005RR.
Ref 8 YTHDF2 Inhibits the Migration and Invasion of Lung Adenocarcinoma by Negatively Regulating the FAM83D-TGFBeta1-SMAD2/3 Pathway. Front Oncol. 2022 Feb 2;12:763341. doi: 10.3389/fonc.2022.763341. eCollection 2022.